Aeon Biopharma Inc
AEON1.100USD
+0.030+2.80%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
12.81MMarket Cap
0.38P/E TTM
More Details of Aeon Biopharma Inc Company
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.
Aeon Biopharma Inc Info
Ticker SymbolAEON
Company nameAeon Biopharma Inc
IPO dateFeb 09, 2021
CEOBancroft (Robert E)
Number of employees5
Security typeOrdinary Share
Fiscal year-endFeb 09
Address5 Park Plaza
CityIRVINE
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code92614
Phone19493546499
Websitehttps://aeonbiopharma.com/
Ticker SymbolAEON
IPO dateFeb 09, 2021
CEOBancroft (Robert E)
Company Executives of Aeon Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert J. (Bob) Palmisano
Mr. Robert J. (Bob) Palmisano
Independent Director
Independent Director
31.46K
--
Mr. Jost Fischer
Mr. Jost Fischer
Independent Chairman of the Board
Independent Chairman of the Board
610.00
-170000.00%
Dr. Chad Oh, M.D.
Dr. Chad Oh, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Alex Wilson
Mr. Alex Wilson
Executive Vice President, Chief Legal Officer, Corporate Secretary
Executive Vice President, Chief Legal Officer, Corporate Secretary
--
--
Mr. Marc Forth
Mr. Marc Forth
Director
Director
--
-973.00%
Dr. Eric Carter, M.D., Ph.D.
Dr. Eric Carter, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Shelley Thune
Ms. Shelley Thune
Independent Director
Independent Director
--
--
Mr. Seongsoo Park
Mr. Seongsoo Park
Director
Director
--
--
Ms. Jennifer Sy
Ms. Jennifer Sy
Principal Financial Officer, Chief Accounting Officer
Principal Financial Officer, Chief Accounting Officer
--
-250.00%
Mr. Robert Bancroft
Mr. Robert Bancroft
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Robert J. (Bob) Palmisano
Mr. Robert J. (Bob) Palmisano
Independent Director
Independent Director
31.46K
--
Mr. Jost Fischer
Mr. Jost Fischer
Independent Chairman of the Board
Independent Chairman of the Board
610.00
-170000.00%
Dr. Chad Oh, M.D.
Dr. Chad Oh, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Alex Wilson
Mr. Alex Wilson
Executive Vice President, Chief Legal Officer, Corporate Secretary
Executive Vice President, Chief Legal Officer, Corporate Secretary
--
--
Mr. Marc Forth
Mr. Marc Forth
Director
Director
--
-973.00%
Dr. Eric Carter, M.D., Ph.D.
Dr. Eric Carter, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Feb 1
Updated: Sun, Feb 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Daewoong Pharma
49.75%
Chernett (Jorey)
4.70%
Dauntless Investment Group, LLC
4.68%
L1 Global Manager Pty Limited
1.94%
Alta Partners L.L.C
1.04%
Other
37.90%
Shareholders
Shareholders
Proportion
Daewoong Pharma
49.75%
Chernett (Jorey)
4.70%
Dauntless Investment Group, LLC
4.68%
L1 Global Manager Pty Limited
1.94%
Alta Partners L.L.C
1.04%
Other
37.90%
Shareholder Types
Shareholders
Proportion
Corporation
51.03%
Investment Advisor
7.24%
Individual Investor
5.57%
Hedge Fund
0.28%
Investment Advisor/Hedge Fund
0.20%
Research Firm
0.13%
Venture Capital
0.07%
Other
35.48%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
67
1.90M
16.13%
--
2025Q3
68
1.90M
16.40%
+93.23K
2025Q2
77
1.87M
15.05%
-257.13K
2025Q1
85
2.12M
3.61%
+1.74M
2024Q4
142
173.55K
77.76%
-9.58K
2024Q3
144
183.13K
72.76%
+52.30K
2024Q2
141
131.03K
75.18%
-1.02K
2024Q1
144
132.04K
79.55%
-289.14K
2023Q4
143
120.98K
87.85%
+3.34K
2023Q3
138
117.65K
75.77%
+54.36K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Chernett (Jorey)
1.13M
9.69%
+1.13M
--
May 27, 2025
Dauntless Investment Group, LLC
1.13M
9.66%
+100.00K
+9.76%
Jun 30, 2025
L1 Global Manager Pty Limited
465.03K
3.93%
+340.58K
+273.69%
Mar 31, 2025
Alta Partners L.L.C
586.34K
5.04%
-43.28K
-6.87%
Jun 30, 2025
Bancroft (Robert E.)
177.10K
1.52%
+177.10K
--
May 14, 2025
The Vanguard Group, Inc.
98.57K
0.83%
+98.57K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
20.70K
0.18%
+20.70K
--
Jun 30, 2025
Blue Owl Capital Holdings LP
42.35K
0.36%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jan 23, 2025
Merger
0→0
Jan 23, 2025
Merger
72→1
Jan 23, 2025
Merger
72→1
Jan 23, 2025
Merger
72→1
Date
Ex-dividend Date
Type
Ratio
Jan 23, 2025
Merger
0→0
Jan 23, 2025
Merger
72→1
Jan 23, 2025
Merger
72→1
Jan 23, 2025
Merger
72→1
